Bio-Path Holdings Inc BPTH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BPTH is a good fit for your portfolio.
News
-
Bio-Path Holdings Provides Clinical Update and Expansion Plans
-
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
-
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
-
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
-
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
-
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting
-
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress
-
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
Trading Information
- Previous Close Price
- $1.78
- Day Range
- $1.77–1.80
- 52-Week Range
- $1.60–23.00
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $3.74 Mil
- Volume/Avg
- 13,175 / 1.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 10
- Website
- https://www.biopathholdings.com
Valuation
|
Metric
|
BPTH
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BPTH
|
|---|---|
Quick Ratio | 0.05 |
Current Ratio | 0.43 |
Interest Coverage | — |
Quick Ratio
BPTH
Profitability
|
Metric
|
BPTH
|
|---|---|
Return on Assets (Normalized) | −239.99% |
Return on Equity (Normalized) | −457.66% |
Return on Invested Capital (Normalized) | −437.08% |
Return on Assets
BPTH
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Hpxqlwmbyn | Jnqtg | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Rcpqgfxkc | Grdyyy | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Vbkrxtpk | Gwldgc | $118.7 Bil | |||
| Moderna Inc
MRNA
| Nlzggqrm | Rmmf | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qzjfpvy | Rwqcbqq | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Tsmyvywx | Tgr | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Wksmyhydr | Hzyj | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Vxvrrfb | Qcqhr | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Tvbwczlbx | Hvlr | $15.0 Bil | |||
| Incyte Corp
INCY
| Yjcxyvwcm | Pnkfhg | $13.5 Bil |